Intelligence artificielle (IA) sur le marché de la découverte de médicaments au Moyen-Orient et en Afrique – Tendances et prévisions de l’industrie jusqu’en 2029

Analyse et perspectives du marché de l'intelligence artificielle (IA) dans la découverte de médicaments au Moyen-Orient et en Afrique  

L’intelligence artificielle (IA) devrait devenir une technologie lucrative dans le secteur de la santé. La mise en œuvre de l’IA réduit le déficit de R&D dans le processus de fabrication des médicaments et contribue à la fabrication ciblée de médicaments. Par conséquent, les sociétés biopharmaceutiques se tournent vers l’IA pour accroître leur part de marché. L’IA pour la découverte de médicaments est une technologie qui utilise des machines pour simuler l’intelligence humaine afin de résoudre des problèmes complexes dans la procédure de développement de médicaments.

L'adoption de solutions d'IA dans le processus d'essais cliniques élimine les obstacles possibles, réduit la durée du cycle des essais cliniques et augmente la productivité et la précision du processus d'essais cliniques. Les avancées technologiques de l'IA pour la découverte de médicaments et la réduction du temps total nécessaire au processus de découverte de médicaments sont d'autres facteurs qui stimulent la croissance du marché au cours de la période de prévision. Cependant, la faible qualité et l'incohérence des données disponibles entraveront la croissance du marché. De plus, les coûts élevés associés à la technologie et les limitations techniques freineront la croissance du marché.

Data Bridge Market Research analyse que le marché de l'intelligence artificielle (IA) dans la découverte de médicaments au Moyen-Orient et en Afrique devrait atteindre la valeur de 548,76 millions USD d'ici 2029, à un TCAC de 47,1 % au cours de la période de prévision. Les logiciels représentent le segment technologique le plus important du marché en raison de l'évolution rapide des avancées technologiques pour commercialiser l'utilisation de l'IA dans le marché de la découverte de médicaments. Ce rapport de marché couvre également en profondeur l'analyse des prix, l'analyse des brevets et les avancées technologiques.        

Middle East and Africa Artificial Intelligence (AI) in Drug Discovery Market Definition

AI has caught the attention and minds of medical technology practitioners in the past few years, as several companies and major research laboratories have worked to perfect these technologies for clinical use. The first commercialized demonstrations of how AI (also known as Deep Learning (DL), Machine Learning (ML), or Artificial Neural Networks (ANNs)) could assist clinicians are now available. These systems could lead to a paradigm shift in clinician workflow, and increase productivity while simultaneously enhancing treatment and patient throughput. AI for drug discovery is a technology that uses machines to simulate human intelligence to solve complicated challenges in the drug development procedure. The adoption of AI solutions in the clinical trial process eliminates possible obstacles, reduces clinical trial cycle time, and increases the productivity and accuracy of the clinical trial process. Therefore, the adoption of these advanced AI solutions in drug discovery processes is gaining popularity amongst life science industry stakeholders. In the pharmaceutical sector, it aids in the discovery of novel compounds, therapeutic target identification, and the development of customized medications. AI platforms used for drug discovery can prove to be a feasible option for deriving insights into the discovery of drugs to treat and minimize the severity of various chronic diseases.

Middle East and Africa Artificial Intelligence (AI) in Drug Discovery Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:

Drivers

• Rise in incidence of chronic diseases propels need for AI in drug discovery

The incidence of chronic diseases is increasing at a rapid pace across the globe. According to the Centers for Disease Control and Prevention (CDC), six in 10 adults in the U.S. have a chronic disease. Furthermore, the CDC also highlights that chronic diseases such as heart disease and diabetes are the leading causes of death in the U.S. Such statistics shed light on the growing prevalence of chronic diseases and the need to bring down the fatality rate caused due to these diseases.

AI platforms used for drug discovery can prove to be a feasible option for deriving insights into the discovery of drugs to treat and minimize the severity of various chronic diseases. Thus, these factors are expected to act as a driver for the market growth during the forecast period.

• Strategic collaborations, partnerships, and products launch

AI has the potential to transform drug discovery by rapidly accelerating the R&D timeline, making drug development cheaper and faster, and improving the probability of approval. AI can also increase the effectiveness of drug repurposing research.

An increase in cross-industry alliances and collaborations drives the market. Rise in relevance of AI in drug discovery & development, and a surge in funding for R&D activities, including AI technology in the field of drug research, are projected to propel the global market growth. Hence, increase in cross-industry collaborations and partnerships is driving the market.

Restraint

• High cost associated with technology and technical limitations

The current healthcare sector is facing several complex challenges, such as the increased cost of drugs and therapies, and society needs specific significant changes in this area. The entire success of AI depends on the availability of a substantial amount of data because these data are used for the subsequent training provided to the system. Access to data from various database providers can incur extra costs for a company. Clinical trials are directed towards establishing the safety and efficacy of a drug product in humans for a particular disease condition and require six to seven years along with a substantial financial investment. However, only one out of ten molecules entering these trials gain successful clearance, which is a massive loss for the industry. These failures can result from inappropriate patient selection, shortage of technical requirements, and poor infrastructure. Thus, increasing costs with the technology is acting as a restraint for the market growth.

Opportunity

• Rise in the investments for R&D

The rise in R&D activities and increasing adoption of cloud-based services and applications will provide beneficial opportunities for market growth.

The industry of AI in biopharma continues to grow after a long period of sepsis. This is reflected in the ongoing flow of investments and increase in the number of collaborations between pharmaceutical corporations and AI companies in 2021 to the previous years. The Biopharma industry’s growth is largely influenced by the active engagement of leading pharmaceutical corporations in AI-related investments. The number of scientific publications in the field of AI in Biopharma, and research collaborations between pharma companies and AI-expertise vendors are rapidly increasing, yet, some pharma corporations are still critical of AI applications. ML and AI applications in the pharmaceutical and healthcare industries lead to the formation of a new interdisciplinary field of data-driven drug discovery in healthcare. Thus, rise in investment in R&D activities is acting as an opportunity for market growth.

Challenge

• Lack of skilled professionals

The shortage of skilled professionals is expected to hamper the market growth. The employees have to re-train or learn new skill sets to work efficiently on the complex AI machines to get the desired results for the drug. This challenge that prevents full-fledged adoption of AI in the pharmaceutical industry includes the lack of skilled personnel to operate AI-based platforms, limited budget for small organizations, apprehension of replacing humans leading to job loss, skepticism about the data generated by AI, and the black box phenomenon (that is, how the conclusions are reached by the AI platform). The shortage of skills acts as a major hindrance to drug discovery through AI, discouraging companies to adopt AI-based machines for drug discovery.

As skill demands are too high, it has manifested as a challenge to retain and manage skill-specified professionals. Moreover, technological advancement is another aspect that leads to the increased demand for skilled professionals. There is an urgent need for the education of professionals for AI-based technology. Lack of trained and experienced professionals and persistent skill gaps limit the employability prospects and access to quality jobs. It is therefore apparent that the availability of professionals equipped with adequate skills is challenging the market growth.

Post-COVID-19 Impact on Middle East and Africa Artificial Intelligence (AI) In Drug Discovery Market

The COVID-19 outbreak had a beneficial impact on the expansion of AI in drug discovery industry due to its widespread use by various organizations for the identification as well as screening of existing medicines used in the treatment of COVID-19. AI is useful in detecting active chemicals for the prevention of SARS-CoV, HIV, SARS-CoV-2, influenza virus, and others. During the pandemic, economies all over the world relied on AI-based medication discovery rather than traditional vaccine detection processes, which take years to create and are equally expensive, contributing to the growth of the market.

Manufacturers are making various strategic decisions to bounce back post-COVID-19. The players are conducting multiple R&D activities to improve the technology involved in the Wireless microphone. With this, the companies will bring advanced and accurate AI software to the market.

Recent Developments

• In March 2022, NVIDIA Corporation launched Clara Holoscan MGX to develop and deploy real-time AI applications. Clara Holoscan MGX expands the Clara Holoscan platform to provide an all-in-one, medical-grade reference architecture, as well as long-term software support, to accelerate innovation in the medical device industry. This will help the company for better AI performance in health sector for surgery, diagnostics, and drug discovery.
• In May 2022, Benevolent AI, a leading clinical-stage AI-enabled drug discovery company, announced that AstraZeneca has selected an additional novel target for Idiopathic Pulmonary Fibrosis (IPF) for its drug development portfolio, resulting in a milestone payment to Benevolent AI.  This is the third novel target from the collaboration that has been identified using the Benevolent Platform across two disease areas, IPF and chronic kidney disease, and subsequently validated and selected for portfolio entry by AstraZeneca. This builds upon the recent extension of the collaboration with AstraZeneca to include two new disease areas, systemic lupus erythematosus, and heart failure, signed in January 2022. This has helped the company to make its collaboration stronger.

Middle East and Africa Artificial Intelligence (AI) In Drug Discovery Market Scope

Middle East and Africa Artificial Intelligence (AI) in drug discovery market is segmented into application, technology, drug type, offering, indication, and end use. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

 APPLICATION

• Novel Drug Candidates
• Drug Optimization and Repurposing Preclinical Testing and Approval
• Drug Monitoring
• Finding New Diseases Associated Targets and Pathways
• Understanding Disease Mechanisms
• Aggregating and Synthesizing Information
• Formation & Qualification of Hypotheses
• De Novo Drug Design
• Finding Drug Targets of an Old Drug
• Others

Based on application, the market is segmented into novel drug candidates, drug optimization and repurposing preclinical testing and approval, drug monitoring, finding new diseases associated targets and pathways, understanding disease mechanisms, aggregating and synthesizing information, formation & qualification of hypotheses, de novo drug design, finding drug targets of an old drug, and others.

 TECHNOLOGY

• Machine Learning (ML)
• Deep Learning (DL)
• Natural Language Processing (NLP)
• Others

Based on technology, the market is segmented into Machine Learning (ML), Deep Learning (DL), Natural Language Processing (NLP), and others.

 DRUG TYPE

• Small Molecule
• Large Molecule

En fonction du type de médicament, le marché est segmenté en petites molécules et en grandes molécules.

OFFRE

• Logiciel
• Services

En fonction de l’offre, le marché est segmenté en logiciels et services.

INDICATION

• Immuno-Oncologie
• Maladies neurodégénératives
• Maladies cardiovasculaires
• Maladies métaboliques
• Autres

En fonction des indications, le marché est segmenté en immuno-oncologie, maladies neurodégénératives, maladies cardiovasculaires, maladies métaboliques et autres.

UTILISATION FINALE

• Sociétés pharmaceutiques et biotechnologiques
• Organismes de recherche sous contrat (ORC)
• Centres de recherche et instituts universitaires
• Autres

En fonction de l'utilisation finale, le marché est segmenté en sociétés pharmaceutiques et biotechnologiques, organisations de recherche sous contrat (CRO), centres de recherche et instituts universitaires, et autres.

Analyse/perspectives régionales du marché de la découverte de médicaments sur l'intelligence artificielle (IA) au Moyen-Orient et en Afrique

Le marché de l’intelligence artificielle (IA) dans la découverte de médicaments au Moyen-Orient et en Afrique est analysé et des informations sur la taille du marché sont fournies par application, technologie, type de médicament, offre, indication et utilisation finale.

Les pays couverts dans ce rapport de marché sont les Émirats arabes unis, Israël, l’Afrique du Sud, l’Arabie saoudite, l’Égypte, le reste du Moyen-Orient et l’Afrique.

• En 2022, le Moyen-Orient et l'Afrique dominent en raison de l'augmentation du financement public. L'Afrique du Sud devrait connaître une croissance en raison de l'augmentation des activités de R&D en matière d'IA dans la découverte de médicaments.

La section pays du rapport fournit également des facteurs d'impact sur les marchés individuels et des changements de réglementation sur le marché national qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que les nouvelles ventes, les ventes de remplacement, la démographie des pays, les actes réglementaires et les tarifs d'importation et d'exportation sont quelques-uns des principaux indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques du Moyen-Orient et d'Afrique et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, ainsi que l'impact des canaux de vente sont pris en compte lors de l'analyse prévisionnelle des données nationales.

Paysage concurrentiel et analyse des parts de marché de l'intelligence artificielle (IA) dans la découverte de médicaments au Moyen-Orient et en Afrique

Le paysage concurrentiel du marché de l'intelligence artificielle (IA) dans la découverte de médicaments au Moyen-Orient et en Afrique fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, les sites et installations de production, les forces et les faiblesses de l'entreprise, le lancement de produits, les pipelines d'essais de produits, les approbations de produits, les brevets, la largeur et l'ampleur du produit, la domination des applications, la courbe de survie technologique. Les points de données ci-dessus fournis ne concernent que l'orientation de l'entreprise vers le marché de l'intelligence artificielle (IA) dans la découverte de médicaments au Moyen-Orient et en Afrique.

Certains des principaux acteurs opérant sur le marché sont NVIDIA Corporation, IBM Corp., Atomwise Inc., Microsoft, Benevolent AI, Aria Pharmaceuticals, Inc., DEEP GENOMICS, Exscientia, Cloud, Insilico Medicine, Cyclica, NuMedii, Inc., Envisagenics, Owkin Inc., BERG LLC, Schrödinger, Inc., XtalPi Inc. et BIOAGE Inc. entre autres.

SKU-69014